The Department of Defense issued 14 separate contract awards to defense contractors Friday, and while Raytheon (NYSE: RTN ) didn't win the biggest of these awards, it did win the second biggest.
Valued at $534.8 million, Raytheon's contract win Friday is a massive firm-fixed-price contract for the production of "AMRAAM" Advanced Medium-Range Air-to-Air Missiles for the U.S. Air Force, and also for the militaries of Oman and Saudi Arabia.
Designated AMRAAM Production Lot 27, this batch of missiles appears to involve the production of nearly 1,800 missiles at reported costs of $300,000 apiece. 51% of the missiles to be produced from this production lot will be sold to U.S. allies Oman and Saudi Arabia, with the balance going to the U.S. Air Force. Delivery is expected to be complete by Jan. 31, 2016.
To date, Raytheon has supplied AMRAAM missiles to 36 different countries around the globe. One of the few modern missiles to have actually been fired in anger, Raytheon boasts that over its lifetime, the AMRAAM has claimed "nine air combat victories" -- nine shoot-downs of enemy aircraft.
Top Quality Companies To Invest In Right Now: China Fund Inc (CHN)
The China Fund, Inc. (the Fund), incorporated on April 28, 1992, is a non-diversified, closed-end management investment company. The Fund�� investment objective is to achieve long-term capital appreciation through investment in companies and other entities with significant assets, investments, production activities, trading or other business interests in the People�� Republic of China, or which derive a significant part of their revenue from the People�� Republic of China.
The China Fund, Inc. may invest in equity-linked securities, such as linked participation notes, equity swaps and zero-strike options, and securities warrants collectively referred to as Access Products. The Fund invests various sectors, including industrials, consumer discretionary, energy, information technology, financials, consumer staples, materials, utilities, healthcare and telecommunications. Martin Currie Inc. serves as the investment manager for the Fund's listed assets. Asian Direct Capital Management is the investment manager for the Fund's assets allocated to direct investments.
Advisors' Opinion:- [By Stephen Leeb, Founder and Research Chairman, Leeb Group]
Healthy economic data, coupled with low inflation, make Chinese stocks attractive as well. Our first choice here is the China Fund (CHN). It holds a diverse portfolio of stocks primarily focused on the Chinese domestic market.
Best Healthcare Technology Companies To Own In Right Now: Stellus Capital Investment Corp (SCM)
Stellus Capital Investment Corporation is an externally managed, closed-end, non-diversified management investment company. The Company was formed to originate and invest primarily in private middle-market companies.
The Company is focusing on a variety of industry sectors, including business services, energy, general industrial, government services, healthcare, software and specialty finance. Its investment activities will be managed by its investment adviser, Stellus Capital Management. It intends to originate and invest primarily in private middle-market companies through first lien, second lien, unitranche and mezzanine debt financing.
Advisors' Opinion:- [By Investing Caffeine]
DISCLOSURE: Sidoxia Capital Management (SCM) and some of its clients hold long positions in certain exchange traded funds (ETFs), but at the time of publishing SCM had no direct position in GS, SCHW, ICE, or any other security referenced in this article. No information accessed through the Investing Caffeine (IC) website constitutes investment, financial, legal, tax or other advice nor is to be relied on in making an investment or other decision. Please read disclosure language on IC Contact page.
- [By Investing Caffeine]
With the stock market reaching all-time record highs (S&P 500: 1900), you would think there would be a lot of cheers, high-fiving, and back slapping. Instead, investors are ignoring the sunny, blue skies and taking off their rose-colored glasses. Rather than securely sleeping like a baby (or relaxing during a three-day weekend) with their investment accounts, people are biting their fingernails with clenched teeth, while searching for a market boogeyman in their closets or under their beds.If you don�� believe me, all you have to do is pick up the paper, turn on the TV, or walk over to the office water cooler. An avalanche of scary headlines that are spooking investors include geopolitical concerns in Ukraine & Thailand, slowing housing statistics, bearish hedge fund managers (i.e., Tepper Einhorn, Cooperman), declining interest rates, and collapsing internet stocks. In other words, investors are looking for things to worry about, despite record corporate profits and stock prices. Peter Lynch, the manager of the Magellan Fund that posted +2,700% in gains from 1977-1990, put short-term stock price volatility into perspective:��ou shouldn�� worry about it. You should worry what are stocks going to be 10 years from now, 20 years from now, 30 years from now.��ather than focusing on immediate stock market volatility and other factors out of your control, why not prioritize your time on things you can control. What investors can control is their asset allocation and spending levels (budget), subject to their personal time horizons and risk tolerances. Circumstances always change, but if people spent half the time on investing that they devoted to planning holiday vacations, purchasing a car, or choosing a school for their child, then retirement would be a lot less stressful. After realizing 99% of all the short-term news is nonsensical noise, the next important realization is stocks are volatile securities, which frequently go down -10 to -20%. As much
Best Healthcare Technology Companies To Own In Right Now: Rexahn Pharmaceuticals Inc (RNN)
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.
Archexin
Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.
Serdaxin
Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.
Zoraxel
Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.
The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.
Advisors' Opinion:- [By James E. Brumley]
With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.
- [By James E. Brumley]
At first glance, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) doesn't look like anything particularly trade-worthy. The stock's now where it was in late October, and where it was in late September, and even where it was in late June. In other words, though RNN has been much higher and much lower than its current price of $0.46 over the course of the past several months, it doesn't look like it's going anywhere - on a net basis - anytime.
Best Healthcare Technology Companies To Own In Right Now: Advanced Energy Industries Inc.(AEIS)
Advanced Energy Industries, Inc., together with its subsidiaries, designs, manufactures, sells, and supports power conversion products that transform power into various usable forms. It offers thin-film deposition power conversion systems, including direct current (DC), pulsed DC mid frequency, and radio frequency (RF) power supplies, as well as matching networks and RF instrumentation; and thermal instrumentation products that provide temperature measurement solutions for applications in which time-temperature cycles affect material properties, productivity, and yield. The company also offers solar power inverters, which provide a transformer-based or transformerless grid-tie photovoltaic (PV) solution to convert renewable solar power into electrical power, as well as integrated monitoring and performance measurement of PV installations. Its power conversion systems are used by semiconductor, solar panel, and similar thin-film manufacturers, such as flat panel display, da ta storage, and architectural glass manufacturers; thermal instrumentation products are used in rapid thermal processing, chemical vapor deposition, and other semiconductor and solar applications requiring non-contact temperature measurement by the semiconductor, solar panels, and LED industries; and solar inverters are used in the residential, commercial, and utility-scale solar projects and installations. In addition, the company provides repair services, conversions, upgrades, and refurbishment services, as well as operations and maintenance service plans for individual PV sites. Advanced Energy Industries, Inc. sells its products through direct sales force, sales representatives, and distributors in North America, Europe, and Asia. The company was founded in 1981 and is headquartered in Fort Collins, Colorado.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Advanced Energy Industries (NASDAQ: AEIS) were 16.74 percent to $17.81 after the company reported downbeat quarterly results and issued a weak Q2 outlook. - [By Evan Niu, CFA]
What: Shares of Advanced Energy (NASDAQ: AEIS ) have dropped today by as much as 14% after the company reported earnings.
So what: Revenue in the first quarter totaled $111.8 million, which translated into non-GAAP earnings per share of $0.29 by the time it reached the bottom line. Those figures were better than consensus estimates of $110.6 million in sales and $0.17 per share in adjusted profit. Guidance was also mostly positive.
Best Healthcare Technology Companies To Own In Right Now: Community Trust Bancorp Inc.(CTBI)
Community Trust Bancorp, Inc. operates as the holding company for Community Trust Bank, Inc. that provides various banking products and services. It accepts various deposit product that include checking accounts, regular and term savings accounts and savings certificates, commercial demand deposit accounts, individual retirement accounts and Keogh plans, non interest bearing deposits, NOW accounts, money market deposits, savings accounts, and certificates of deposit and other time deposits. The company?s loan portfolio comprises residential and commercial real estate loans; commercial loans; commercial, construction, mortgage, and personal loans; and lease-financing, lines of credit, revolving lines of credit, term loans, and other specialized loans, including asset-based financing. It also provides full service securities brokerage services; annuity and life insurance products; trust services; debit cards; cash management services to corporate and individual customers; l etters of credit; safe deposit boxes; and funds transfer services. In addition, the company acts as a trustee of personal trusts, an executor of estates, trustee for employee benefit trusts, registrar, transfer agent, paying agent for bond and stock issues; and depositor for securities, as well as provides full service brokerage services. Community Trust operates 80 banking locations in eastern, northeastern, central, and south central Kentucky; southern West Virginia; and northeastern Tennessee, as well as 5 trust offices across Kentucky. The company was founded in 1903 and is headquartered in Pikeville, Kentucky.
Advisors' Opinion:- [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
HRL is trading at a premium to all four valuations above. The stock is trading at a 27.6% premium to its calculated fair value of $35.92. HRL did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
HRL earned one Star in this section for 2.) above. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. The company has paid a cash dividend to shareholders every year since 1928 and has increased its dividend payments for 48 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
HRL earned a Star in this section for its NPV MMA Diff. of the $984. This amount is in excess of the $500 target I look for in a stock that has increased dividends as long as HRL has. If HRL grows its dividend at 13.2% per year, it will take 7 years to equal a MMA yielding an estimated 20-year average rate of 3.68%.
Memberships and Peers: HRL is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achiever - [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
GWW is trading at a premium to all four valuations above. The stock is trading at a 10.0% premium to its calculated fair value of $219.95. GWW did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
GWW earned three Stars in this section for 1.), 2.) and 3.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. GWW earned a Star for having an acceptable score in at least two of the four Key Metrics measured.
Rolling 4-yr Div. > 15% means that dividends grew on average in excess of 15% for each consecutive 4 year period over the last 10 years (2003-2006, 2004-2007, 2005-2008, etc.) I consider this a key metric since dividends will double every 5 years if they grow by 15%. The company has paid a cash dividend to shareholders every year since 1965 and has increased its dividend payments for 42 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked
Best Healthcare Technology Companies To Own In Right Now: Neogen Corporation(NEOG)
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. The company?s Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues, and general sanitation concerns. Its products also comprise bioluminescence-based diagnostic technology for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers, meat and poultry processors, seafood processors, fruit and vegetable producers, grain producers and processors, food and beverage processors, and dairies; laboratories and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products; and various re gulatory agencies. The company?s Animal safety segment provides pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals and diagnostic products, and genetic testing services to the animal safety market. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm animals and racing animals, such as horses, greyhounds, and camels; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. This segment?s products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. In addition, it offers various products for researchers to detect biologically-active substances; and proprietary substrates for other diagnostic test kit manufacturers. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in La nsing, Michigan.
Advisors' Opinion:- [By MONEYMORNING.COM]
And with very quick gains of 9% in BRF SA (NYSE ADR: BRFS), 5.2% in South American agricultural play Adecoagro SA (NYSE: AGRO) and 1.6% in high-tech agribusiness player Neogen Corp. (Nasdaq: NEOG), we're doing well with our plays on (pockets of) accelerating U.S. inflation.
No comments:
Post a Comment